# EDGAR Filing Document

**Accession Number:** 0000861177
**File Stem:** 0000861177-23-000003
**Filing Date:** 2023-2
**Character Count:** 10554
**Document Hash:** 490188d25a3f5ad63e97cb1e41eb7d87
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000861177-23-000003.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0000861177-23-000003

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prelude Therapeutics Inc
- **CENTRAL INDEX KEY:** 0001678660
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 811384762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91717
- **FILM NUMBER:** 23615601

**BUSINESS ADDRESS:**
- **STREET 1:** 200 POWDER MILL ROAD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** (302) 547-3768

**MAIL ADDRESS:**
- **STREET 1:** 200 POWDER MILL ROAD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prelude Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20160630
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UBS ASSET MANAGEMENT AMERICAS INC
- **CENTRAL INDEX KEY:** 0000861177
- **STANDARD INDUSTRIAL CLASSIFICATION:** UNKNOWN SIC - 0000 [0000]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** ONE NORTH WACKER DRIVE
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 60606

**MAIL ADDRESS:**
- **STREET 1:** ONE NORTH WACKER DRIVE
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UBS GLOBAL ASSET MANAGEMENT AMERICAS INC
- **DATE OF NAME CHANGE:** 20030122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRINSON PARTNERS INC/IL
- **DATE OF NAME CHANGE:** 19930715

```

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Initial Filing)
Prelude Therapeutics Inc

(Name of Issuer)
-----------------------------------------------------------
Common stock, par value $0.0001 per share

(Title of Class of Securities)
-----------------------------------------------------------

74065P101
(CUSIP Number)

-----------------------------------------------------------

December 30, 2022
(Date of Event Which Requires Filing of this Statement)
-----------------------------------------------------------

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

/X/ Rule 13d 1(b)
/ / Rule 13d 1(c)
/ / Rule 13d 1(d)

*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be filed for the purpose of Section
18 of the Securities Exchange Act of 1934 (Act) or otherwise
subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however,
see the Notes).

1.   Names of reporting persons

UBS Group AG (for the benefit and on behalf of the UBS Asset
Management division of UBS Group AG (see Item 7)

-----------------------------------------------------------

2.   Check the appropriate box if a member of a group
a  / /
b  / /   See Item 8 of attached schedule
-----------------------------------------------------------
3.  SEC use only
-----------------------------------------------------------
4.  Citizenship or place of organization

Switzerland
-----------------------------------------------------------

Number of shares beneficially owned by each reporting person with:

Number of       5.  Sole Voting Power 	      2,325,935
Shares Bene-    6.  Shared Voting Power       0
ficially        7.  Sole Dispositive Power    0
Owned by Each   8.  Shared Dispositive Power  2,507,992
-----------------------------------------------------------

9.  Aggregate Amount Beneficially Owned by Each Reporting Person:

2,507,992

-----------------------------------------------------------

10. Check if the aggregate amount in Row (9) excludes certain shares
(see instructions)

Shares / /

-----------------------------------------------------------

11.  Percent of class represented by amount in Row (9)

5.24%

-----------------------------------------------------------

12.  Type of reporting person (see instructions)
HC

-----------------------------------------------------------

Item 1(a) Name of issuer: Prelude Therapeutics Inc
-----------------------------------------------------------

Item 1(b) Address of issuer's principal executive offices:

Prelude Therapeutics Inc
200 Powder Mill Road
Wilmington, DE 19803

-----------------------------------------------------------

2(a) Name of person filing:
UBS Group AG
-----------------------------------------------------------

2(b) Address or principal business office or, if none, residence:

UBS Group AG
Bahnhofstrasse 45
PO Box CH-8021
Zurich, Switzerland

-----------------------------------------------------------

2(c) Citizenship:
Switzerland
-----------------------------------------------------------

2(d) Title of class of securities:

Common stock, par value $0.0001 per share
-----------------------------------------------------------

2(e) CUSIP No.:  74065P101

-----------------------------------------------------------

Item 3.	If this statement is filed pursuant to Sections
240.13d 1(b) or 240.13d 2(b) or (c), check whether the person
filing is a:
(a) / /	Broker or dealer registered under section 15 of the
Act (15 U.S.C. 78o);
(b) / /	Bank as defined in section 3(a)(6) of the Act
(15 U.S.C. 78c);
(c) / /	Insurance company as defined in section 3(a)(19) of
the Act (15 U.S.C. 78c);
(d) / /	Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a 8);
(e / /	An investment adviser in accordance with Section
240.13d 1(b)(1)(ii)(E);
(f) / /	An employee benefit plan or endowment fund in
accordance with Section 240.13d 1(b)(1)(ii)(F);
(g) /X/ A parent holding company or control person in
accordance with Section 240.13d 1(b)(1)(ii)(G);
(h) / / A savings associations as defined in Section 3(b)
of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) / /	A church plan that is excluded from the definition
of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a 3);
(j) / /	A non-U.S. institution in accordance with
Section 240.13d 1(b)(1)(ii)(J);
(k) / /	Group, in accordance with Section
240.13d 1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Section 240.13d  1(b)(1)(ii)(J), please specify the type of
institution: ________________________________

-----------------------------------------------------------

Item 4.	Ownership

Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.

(a) Amount beneficially owned: 2,507,992.
(b) Percent of class:   5.24%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 2,325,935.
(ii) Shared power to vote or to direct the vote  ____.
(iii) Sole power to dispose or to direct the disposition of ___.
(iv) Shared power to dispose or to direct the disposition of
 2,507,992.

-----------------------------------------------------------

Item 5.	Ownership of 5 Percent or Less of a Class. If this statement
is being filed to report the fact that as of the date hereof the
reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following / /.
Dissolution of a group requires a response to this item.
Item 6.	Ownership of More than 5 Percent on Behalf of Another Person.
Accounts managed on a discretionary basis by the UBS Asset Management
division of UBS Group AG (UBS AM) have the right to receive or the
power to direct the receipt of dividends from, or the proceeds from
the sale of, the securities.  To the best of our knowledge, no account
holds more than 5 percent of the outstanding securities being reported
in this filing.

-----------------------------------------------------------

 Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person.

Identification:  UBS Asset Management (Americas) Inc.
Classification:  IA

In addition to UBS Group AG, the following UBS Asset Management
affiliates and subsidiaries are part of the UBS
Asset Management division included in this filing: UBS Asset
Management (Americas) Inc., UBS Asset Management (Canada) Inc.,
UBS Asset Management (Deutschland) GmbH, UBS Asset Management
(Japan) Ltd, UBS Asset Management (Singapore) Ltd, UBS Asset
Management (UK) Limited, UBS Fund Management (Luxembourg) S.A.,
and UBS Fund Management (Switzerland) AG

-----------------------------------------------------------

Item 8. Identification and Classification of Members of the Group.
UBS AM is composed of wholly-owned subsidiaries and branches of UBS
Group AG.  UBS Group AG is reporting direct and indirect beneficial
ownership of holdings.  None of the reporting persons affirm the
existence of a group within the meaning of Rule 13d 5(b)(1).
-----------------------------------------------------------

Item 9. Notice of Dissolution of Group.
N/A
-----------------------------------------------------------

Item 10.	Certifications

By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired
and are held for the purpose of or with the effect of changing
or influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect
other than activities solely in connection with a nomination
under Section 240.14a 11.

Signatures

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.

Date:  02/13/2023

UBS Asset Management (Americas), Inc.

Signature: /s/ Lissette Resnick
Name: Lissette Resnick
Title: Director

Date:  02/13/2023

Signature: /s/ Barry J. Mullen
Name: Barry J. Mullen
Title: Chief Compliance Officer

```